Associate Director, Marketing
Orca Bio- Full Time
- Junior (1 to 2 years)
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. We are seeking a dynamic and proactive individual to join our Cytokinetics’ team in an Opinion Leader Engagement (OLE) role. This is a field based, commercial role responsible for establishing and maintaining strong relationships with commercial Key Opinion Leaders (KOLs) in an assigned geography. This role will report to the Regional Business Director, East and the ideal candidate will reside within the East Region. Activities include conducting in-person and virtual engagements using approved materials to support commercial related activities and processes involving KOLs. The OLE will be a key point of contact between their assigned KOLs and Cytokinetics to advance the organization’s commercial goals and provide KOL perspectives into Cytokine’s long-term brand vision and strategy.
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility.
Develops drugs for muscle function disorders
Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.